- Sanofi nixes Kymab-originated OX40L antibody in atopic dermatitisSanofi has decided to stop working on a drug for eczema it had hoped would be a successor to its immunological megablockbuster Dupixent. The French pharma said that it won’t seek ...Endpoints · 1d ago↗ source
- Merck stages expanded access to monthly HIV PrEP pill ahead of approvalFollowing in the footsteps of Gilead, Merck has signed voluntary licensing agreements to enable access to its investigational HIV PrEP pill alimatravir ahead of any regulatory submissions.Fierce Biotech · 1d ago↗ source
- Opinion: I may be one of the last middle-class medical students who could afford to become a doctorA federal loan program made it possible for Gauri Gurumurthy to pursue medicine. Now that program is changing.